Senators: Long

Sen.EdMarkeyofMassachusetts(above)andSen.JoeManchinofWestVirginiahadwordsofwarningforFDACommissioner 另外，受行业景气度下滑及影视剧作品播出政策变化等影响，在资产负债表日后，电视剧《东宫》等项目发生了销售合同变更等情况，唐德影视根据新的业务情况变化，调整相应的营业收入和营业成本。




focus

author：entertainment    Page View：73388
Novo Nordisk headquarters -- health coverage from STAT
LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

advertisement

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Changes to biosimilar regulatory framework must prioritize patients
Next article： Cancer drug shortages should be causing more outrage